Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms

NCT02790034 is registered in ClinicalTrials.gov with Newron Pharmaceuticals SPA as lead sponsor.

NCT NCT02790034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02790034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms
Lead sponsor
Newron Pharmaceuticals SPA
Phase
Phase 2/3
Overall status
Terminated
Start date
October 26, 2016
Completion date
May 4, 2020
Enrollment
129 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

rett syndrome